Attached files
| file | filename |
|---|---|
| EX-21.1 - EXHIBIT 21.1 - Assertio Therapeutics, Inc | exhibit211-subsidiaries.htm |
| EX-32.2 - EXHIBIT 32.2 - Assertio Therapeutics, Inc | exhibit322-fy2019.htm |
| EX-32.1 - EXHIBIT 32.1 - Assertio Therapeutics, Inc | exhibit321-fy2019.htm |
| EX-31.2 - EXHIBIT 31.2 - Assertio Therapeutics, Inc | exhibit312-fy2019.htm |
| EX-31.1 - EXHIBIT 31.1 - Assertio Therapeutics, Inc | exhibit311-fy2019.htm |
| EX-4.5 - EXHIBIT 4.5 - Assertio Therapeutics, Inc | exhibit45-descriptionofcom.htm |
| 10-K - 10-K - Assertio Therapeutics, Inc | asrt-12312019x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1) | Registration Statements (Forms S-3 No. 333-53486, No. 333-66688, No. 333-86542, No. 333-104956, No. 333-197433 and No. 333-223420) and related Prospectuses of Assertio Therapeutics, Inc., |
2) | Registration Statements (Forms S-8 No. 333-116697, No. 333-145291, No. 333-156538, No. 333-167015, No. 333-181710, No. 333-196263, No. 333-211642, No. 333-211643, No. 333-224924, No. 333-228290 and No. 333-231366) pertaining to the 2004 Equity Incentive Plan, the Second and Amended and Restated 2004 Employee Stock Purchase Plan, the Amended and Restated 2014 Omnibus Incentive Plan and the Inducement Award Program of Assertio Therapeutics, Inc. |
of our reports dated March 10, 2020, with respect to the consolidated financial statements and schedule of Assertio Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Assertio Therapeutics, Inc., included in this Annual Report (Form 10-K) of Assertio Therapeutics, Inc. for the year ended December 31, 2019.
/s/Ernst & Young LLP
Chicago, Illinois
March 10, 2020